A Multicenter, Randomized, Open-Label, 4-Week Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Once Daily Treatment Compared to K-877-IR Twice Daily Treatment in Adult Patients With Fasting Triglyceride Levels
Latest Information Update: 24 Dec 2023
At a glance
- Drugs Pemafibrate (Primary) ; Pemafibrate
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Kowa Research Institute
Most Recent Events
- 25 Feb 2021 Status changed from recruiting to completed.
- 30 Jun 2020 New trial record